BioXcel Therapeutics (BTAI) Return on Capital Employed (2018 - 2026)

BioXcel Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 325.86% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 73792.0% year-over-year to 325.86% in Q1 2026; TTM through Mar 2026 was 325.86%, a 73792.0% increase from a year earlier, with the FY2025 full-year figure at 410.29%, up 60931.0% from the prior year.
• Return on Capital Employed eased to 325.86% in Q1 2026 per BTAI's latest filing, from 556.23% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 4316.81% in Q2 2025 and bottomed at 412.06% in Q1 2025.
• The 5-year median for Return on Capital Employed is 109.23% (2023), against an average of 272.95%.
• Across the five-year window, Return on Capital Employed slumped 20426 bps in 2023 and surged 455212 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 82.96% in 2022, then sank by 246 bps to 287.22% in 2023, then slipped by 9 bps to 314.49% in 2024, then surged by 277 bps to 556.23% in 2025, then slumped by 41 bps to 325.86% in 2026.
• Per Business Quant, the three latest BTAI Return on Capital Employed figures stand at 325.86% (Q1 2026), 556.23% (Q4 2025), and 2015.99% (Q3 2025).